| MNST |
Report |
Net revenue |
BEAT |
pred ~$2.470B vs. cons $2.437B |
MEDIUM |
| MNST |
Report |
Operating diluted EPS |
BEAT |
pred ~$0.593 vs. cons $0.581 |
MEDIUM |
| MNST |
Report |
Gross profit |
IN-LINE |
pred ~$1.335B vs. cons $1.328B |
MEDIUM |
| MNST |
Guide |
International trajectory (Q3 2026) |
BETTER |
commentary supports ~$1.10B vs. cons $1.080B |
LOW |
| MNST |
Guide |
Gross-margin / costs (Q3-Q4 2026) |
UNCHANGED |
continued modest sequential cost pressure vs. Q3 gross-profit cons $1.340B |
MEDIUM |
| MNST |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.5% |
— |
LOW |
| MNST |
Return |
5-day cumulative residual |
+1.0% (FADE) |
FADE - margin and multiple debate limits follow-through |
LOW |